ANZCTR - Registration

Please note that the ANZCTR website will be unavailable from 1:00pm until 2:00pm (AEST) on Thursday 10th of April for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.

With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.

Reset your password and enable multi-factor authentication (MFA)

For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.

Go to the Login page, click ‘reset password’ and follow the instructions.
Check your email for the link to set a new password.
Create a new password that meets requirements.
Return to the Login page and enter your new password. A verification code will be sent to your email.
Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01659658

Registration number

NCT01659658

Ethics application status

Date submitted

2/08/2012

Date registered

8/08/2012

Titles & IDs

Public title

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Scientific title

A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Secondary ID [1]

2011-005468-10

Secondary ID [2]

C16011

Universal Trial Number (UTN)

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Relapsed or Refractory Systemic Light Chain Amyloidosis

Condition category

Condition code

Metabolic and Endocrine

Metabolic disorders

Metabolic and Endocrine

Other metabolic disorders

Human Genetics and Inherited Disorders

Other human genetics and inherited disorders

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Treatment: Drugs - IXAZOMIB
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Melphalan
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Thalidomide
Treatment: Drugs - Lenalidomide

Experimental: Arm A: Ixazomib + Dexamethasone - Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 and dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22 of each 28-day cycle for up to a maximum of 95.2 months. Dexamethasone was increased up to 40 mg/day after 4 weeks, if tolerated.

Active comparator: Arm B: Dexamethasone + Melphalan - Participants received dexamethasone 20 mg, orally, and melphalan 0.22 mg/kg, orally once on Days 1 through 4 of each 28-day cycle, for up to a maximum of 72.4 months.

Active comparator: Arm B: Dexamethasone + Cyclophosphamide - Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22, and cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 of each 28-day cycle for up to a maximum of 72.4 months.

Active comparator: Arm B: Dexamethasone + Thalidomide - Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle, and thalidomide daily at a starting dose of 50 mg and increased, as tolerated, to a maximum of 200 mg, orally for up to a maximum of 72.4 months.

Active comparator: Arm B: Dexamethasone + Lenalidomide - Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle and lenalidomide 15 mg, orally, once on Days 1 through 21 every 28 days for up to a maximum of 72.4 months.

Treatment: Drugs: IXAZOMIB
IXAZOMIB capsules

Treatment: Drugs: Dexamethasone
Dexamethasone tablets

Treatment: Drugs: Melphalan
Melphalan tablets

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide tablets

Treatment: Drugs: Thalidomide
Thalidomide capsules

Treatment: Drugs: Lenalidomide
Lenalidomide capsules

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

Control group

Outcomes

Primary outcome [1]

Percentage of Participants With Overall Hematologic Response

Assessment method [1]

Overall hematologic response was defined as the percentage of participants with complete response (CR), very good partial response (VGPR) and partial response (PR) based on central laboratory results and the 2010 International Society of Amyloidosis (ISA) Consensus Criteria as assessed by an adjudication committee. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of free light chain (FLC) ratio. VGPR: differential free light chain (difference between involved and uninvolved FLC levels; dFLC) \< 40 mg/L. PR: =50% reduction in dFLC. Percentages were rounded off to the nearest decimal.

Timepoint [1]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Primary outcome [2]

2-Year Vital Organ (Heart or Kidney) Deterioration and Mortality Rate

Assessment method [2]

Cardiac (Heart) deterioration was defined as the need for hospitalization for heart failure. Kidney deterioration was defined as progression to end-stage renal disease (ESRD) with the need for maintenance dialysis or renal transplantation. Vital organ deterioration was evaluated by an adjudication committee. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [2]

Up to 2 years

Secondary outcome [1]

Percentage of Participants With Complete Hematologic Response

Assessment method [1]

Complete hematologic response was defined as the percentage of participants with CR based on central laboratory results and the 2010 ISA Consensus Criteria as assessed by the investigator. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of FLC ratio. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [1]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [2]

Overall Survival

Assessment method [2]

Overall survival was defined as the time from the date of randomization to the date of death. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [2]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [3]

Progression Free Survival (PFS)

Assessment method [3]

PFS was defined as the time from the date of randomization to the date of first documentation of hematologic disease progression, or organ (cardiac or renal) progression, or death due to any cause, whichever occurred first according to central laboratory results and ISA criteria as evaluated by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [3]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [4]

Hematologic Disease Progression Free Survival

Assessment method [4]

Hematologic disease PFS was defined as the time from the date of randomization to the date of first documentation of hematologic PD according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurred first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [4]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [5]

Time to Vital Organ (Heart or Kidney) Deterioration and Mortality Rate

Assessment method [5]

Time to vital organ deterioration or death was assessed by the investigator and defined as the time from randomization to vital organ (heart or kidney) deterioration or death, whichever occurs first. Cardiac deterioration is defined as the need for hospitalization for heart failure. Kidney deterioration is defined as progression to ESRD with the need for maintenance dialysis or renal transplantation. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [5]

From randomization to time of vital organ deterioration or death (up to 115 months)

Secondary outcome [6]

Percentage of Participants With Best Vital Organ (Cardiac and/or Kidney) Response

Assessment method [6]

Vital organ (heart and kidney) response rate was defined as the percentage of participants who achieved vital organ response according to central laboratory results and ISA criteria as evaluated by an adjudication committee. A vital organ response was defined as response of 1 or 2 of the involved vital organs with no change from Baseline in the rest of involved vital organs. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [6]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [7]

Vital Organ Progression Free Survival

Assessment method [7]

Vital organ PFS is defined as the time from the date of randomization to the date of first documentation of progression of vital organ (heart or kidney) according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurs first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [7]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [8]

Duration of Hematologic Response

Assessment method [8]

Duration of hematologic response (DOR) was defined as the time from the date of first documentation of a hematologic response to the date of first documented hematologic disease progression as determined by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [8]

From time of first documented response to disease progression (up to 115 months)

Secondary outcome [9]

Number of Participants With Serious Adverse Events (SAEs)

Assessment method [9]

A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or medically important event.

Timepoint [9]

From first dose of study drug through 30 days after administration of the last dose of study drug (up to 115 months)

Secondary outcome [10]

Time To Treatment Failure (TTF)

Assessment method [10]

TTF was defined as the time from randomization to the date of first documented treatment failure. Treatment failure was defined as: 1) death due to any cause; 2) hematologic progression or major organ progression according to central laboratory results and ISA criteria as evaluated by the investigator; 3) clinically morbid organ disease requiring additional therapy; or 4) withdrawn for any reason. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [10]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Secondary outcome [11]

Time To Subsequent Anticancer Treatment

Assessment method [11]

Time to subsequent anticancer therapy was defined as the time from randomization to the first date of subsequent anticancer therapy. Participants without subsequent anticancer therapy were censored at the date of death or last known to be alive. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [11]

From first dose of study drug until subsequent anticancer treatment (up to 115 months)

Secondary outcome [12]

Change From Baseline in 36-item Short Form General Health Survey (SF-36) Mental Component Summary Score at Week 28 of the PFS Follow-up

Assessment method [12]

SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [12]

Baseline, Week 28 of the PFS Follow-up

Secondary outcome [13]

Change From Baseline in SF-36 Physical Component Summary Score at Week 28 of the PFS Follow-up

Assessment method [13]

Timepoint [13]

Baseline, Week 28 of the PFS Follow-up

Secondary outcome [14]

Change From Baseline in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) Score at Week 28 of the PFS Follow-up

Assessment method [14]

The FACT/GOG-Ntx is a participant completed questionnaire that comprises 11 individual items evaluating symptoms of neurotoxicity on a 5-point scale where: 0=not at all (best) to 4=very much for a total possible score of 0 to 44. Symptom scores are inverted so that higher scores of FACT/GOG-Ntx indicate higher quality of life or functioning. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [14]

Baseline, Week 28 of the PFS Follow-up

Secondary outcome [15]

Change From Baseline in Amyloidosis Symptom Scale Total Score at Week 28 of the PFS Follow-up

Assessment method [15]

The amyloidosis symptom scale questionnaire is a participant completed questionnaire that evaluates symptom severity of 3 symptoms: Swelling, Shortness of Breath and Dizziness, each rated on an 11-point scale where: 0=no symptoms to 10=very severe symptoms. Higher scores indicate worsening of symptoms. Total Score is the sum of all responses from the amyloidosis symptom scale ranging from 0 to 30. Higher scores represent higher levels of symptomatology or problems and a negative change from baseline indicates improvement. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [15]

Baseline, Week 28 of the PFS Follow-up

Secondary outcome [16]

Number of Participants in Each Category of the EuroQol 5-Dimensional (EQ-5D) Questionnaire Score

Assessment method [16]

The European Quality of Life (EuroQOL) 5-Dimensional (EQ-5D) is a patient completed questionnaire consisting of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 3 possible choices: no problems to extreme problems. Higher scores=worsening of the quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [16]

At Week 28 of the OS follow-up

Secondary outcome [17]

EuroQol 5-Dimension 3-Level (EQ-5D-3L) Visual Analogue Scale Score

Assessment method [17]

The EQ visual analogue scale (VAS) records the participant's self-rated health on a 20 centimeter vertical VAS that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Baseline is defined as the value collected at the time closest to, but prior to, the start of study drug administration. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [17]

At Week 28 of the OS follow-up

Secondary outcome [18]

Plasma Concentration of Ixazomib

Assessment method [18]

As prespecified in the protocol, data for this outcome measure was planned to be collected for ixazomib arm group only.

Timepoint [18]

Cycle 1, Day 1: 1, 4 hours postdose, Day 14: 144 hours postdose; Cycle 2, Day 1: predose, Day 14: 144 hours postdose; Cycles 3 to 10, Day 1: predose (cycle length=28 days)

Secondary outcome [19]

Number of Hospitalizations

Assessment method [19]

A hospitalization was defined as at least one overnight stay in an intensive care unit and/or non-intensive care unit. If a single hospitalization included both an intensive care unit stay and a non-intensive care unit stay, the hospitalization was counted only once (as an intensive care unit stay). The mean number of hospitalizations is reported in this outcome measure. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.

Timepoint [19]

From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Eligibility

Key inclusion criteria

1. Male or female participants 18 years or older.
2. Biopsy-proven diagnosis of primary systemic light chain amyloidosis (AL amyloidosis) according to the following standard criteria:

1. Histochemical diagnosis of amyloidosis, as based on tissue specimens with Congo red staining with exhibition of an apple-green birefringence
2. If clinical and laboratory parameters insufficient to establish AL amyloidosis or in cases of doubt, amyloid typing may be necessary.
3. Measurable disease as defined by serum differential free light chain concentration (dFLC, difference between amyloid forming [involved] and nonamyloid forming [uninvolved] free light chain [FLC]) = 50 mg/L.
4. Objective, measurable major (cardiac or renal) organ amyloid involvement as defined as follows (amyloid involvement of at least 1 required):

1. Cardiac involvement is defined as the presence of a mean left ventricular wall thickness on echocardiogram greater than 12 mm in the absence of other potential causes of left ventricular hypertrophy (controlled hypertension is allowed) with a noncardiac biopsy showing amyloid, or a positive cardiac biopsy in the presence of clinical or laboratory evidence of involvement. If there is isolated cardiac involvement, then typing of amyloid deposits is recommended.
2. Renal involvement is defined as proteinuria (predominantly albumin) >0.5 g/day in a 24-hour urine collection.

Note: Amyloid involvement of other organ systems is allowed, but not required.
5. Must be relapsed or refractory after 1 or 2 prior therapies. For this protocol, relapsed is defined as progressive disease (PD) documented more than 60 days after last dose; refractory is defined as documented absence of hematologic response or hematologic progression on or within 60 days after last dose of prior therapy.

1. Participant must not have been previously treated with proteasome inhibitors. (The sponsor reserves the right to open the study to proteasome inhibitor-exposed participants in the future, at some time point after the first interim analysis (IA). In that case, the participant may not be refractory to proteasome inhibitor therapy.)
2. Given that the physician may select from an offered list of regimens to treat a specific participant, the participant may be refractory to an agent/s listed within the list of offered treatment choices
3. Must have recovered (ie, = Grade 1 toxicity or participant's baseline status) from the reversible effects of prior therapy
4. If a participant has received a transplant as his/her first-line therapy, he/she must be at least 3 months post transplantation and recovered from the side effects of the stem cell transplant.
6. Must meet criteria for 1 of the following AL Amyloidosis Risk Stages (as defined by N-terminal proBNP [NT-proBNP] cut-off of < 332 pg/mL and troponin T cut-off of 0.035 ng/mL as thresholds):

1. Stage 1: both NT-proBNP and troponin T under threshold
2. Stage 2: either NT-proBNP or troponin T (but not both) over threshold;
3. Stage 3: both NT-proBNP and troponin T over threshold (but NT-proBNP < 8000 pg/mL)
7. Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.
8. Clinical laboratory values:

1. Absolute neutrophil count = 1000/µL
2. Platelet count = 75,000/µL
3. Total bilirubin = 1.5 upper limit of normal (ULN), except for participants with Gilbert's syndrome as defined by > 80% unconjugated bilirubin and total bilirubin = 6 mg/dL
4. Alkaline phosphatase = 5 x ULN
5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =3 x ULN
6. Calculated creatinine clearance = 30 mL/min
9. Female participants who:

1. If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study treatment, AND
2. Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
3. Agree to practice true abstinence when this is line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.).

Male participants, even if surgically sterilized (ie, status post vasectomy), who:
1. Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, AND
2. Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
3. Agree to practice true abstinence when this is line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
10. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

1. Amyloidosis due to mutations of the transthyretin gene or presence of other non-AL amyloidosis.
2. Female participants who are lactating, breast feeding, or pregnant.
3. Medically documented cardiac syncope, uncompensated New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, myocardial infarction within the previous 6 months, unstable angina pectoris, clinically significant repetitive ventricular arrhythmias despite antiarrhythmic treatment, or severe orthostatic hypotension or clinically important autonomic disease.
4. Clinically overt multiple myeloma, according to the International Myeloma Working Group (IMWG) criteria with at least 1 of the following:

1. Bone lesions
2. Hypercalcemia, defined as a calcium of > 11 mg/dL
5. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
6. Requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered to be investigational or which would be considered as a treatment of AL amyloidosis. However, participants may be on chronic steroids (maximum dose 20 mg/day prednisone or equivalent) if they are being given for disorders other than amyloidosis (eg, adrenal insufficiency, rheumatoid arthritis, etc.).
7. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
8. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection.
9. Psychiatric illness/social situations that would limit compliance with study requirements.
10. Known allergy to boron, MLN9708, any of the study treatments, their analogues, or excipients.
11. Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment.
12. Diagnosed or treated for another malignancy within 3 years (or 5 years for participants in France) before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Open (masking not used)

Who is / are masked / blinded?

Intervention assignment

Parallel

Other design features

Phase

Phase 3

Type of endpoint/s

Statistical methods / analysis

Recruitment

Recruitment status

Stopped early

Data analysis

Reason for early stopping/withdrawal

Other reasons

Date of first participant enrolment

Anticipated

Actual

26/12/2012

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

11/07/2022

Sample size

Target

Accrual to date

Final

177

Recruitment in Australia

Recruitment state(s)

NSW,QLD,VIC,WA

Recruitment hospital [1]

Westmead Hospital - Westmead

Recruitment hospital [2]

Princess Alexandra Hospital - Woolloongabba

Recruitment hospital [3]

Box Hill Hospital - Box Hill

Recruitment hospital [4]

Sir Charles Gairdner Hospital - Nedlands

Recruitment postcode(s) [1]

214 - Westmead

Recruitment postcode(s) [2]

4102 - Woolloongabba

Recruitment postcode(s) [3]

3128 - Box Hill

Recruitment postcode(s) [4]

6009 - Nedlands

Recruitment outside Australia

Country [1]

United States of America

State/province [1]

California

Country [2]

United States of America

State/province [2]

Illinois

Country [3]

United States of America

State/province [3]

Indiana

Country [4]

United States of America

State/province [4]

Massachusetts

Country [5]

United States of America

State/province [5]

Michigan

Country [6]

United States of America

State/province [6]

Minnesota

Country [7]

United States of America

State/province [7]

Missouri

Country [8]

United States of America

State/province [8]

New York

Country [9]

United States of America

State/province [9]

Ohio

Country [10]

United States of America

State/province [10]

Tennessee

Country [11]

United States of America

State/province [11]

Texas

Country [12]

United States of America

State/province [12]

Wisconsin

Country [13]

Brazil

State/province [13]

Santa Catarina

Country [14]

Brazil

State/province [14]

Rio de Janeiro

Country [15]

Brazil

State/province [15]

Sao Paulo

Country [16]

Canada

State/province [16]

Alberta

Country [17]

Canada

State/province [17]

British Columbia

Country [18]

Canada

State/province [18]

Ontario

Country [19]

Czechia

State/province [19]

Moravskoslezsk Kraj

Country [20]

Czechia

State/province [20]

Praha, Hlavni Mesto

Country [21]

Denmark

State/province [21]

Aahus

Country [22]

Denmark

State/province [22]

Copenhagen

Country [23]

France

State/province [23]

Loire-Atlantique

Country [24]

France

State/province [24]

Lille

Country [25]

France

State/province [25]

Limoges

Country [26]

France

State/province [26]

Paris

Country [27]

France

State/province [27]

Toulouse

Country [28]

Germany

State/province [28]

Berlin

Country [29]

Germany

State/province [29]

Hamburg

Country [30]

Germany

State/province [30]

Heidelberg

Country [31]

Greece

State/province [31]

Achaia

Country [32]

Greece

State/province [32]

Athens

Country [33]

Israel

State/province [33]

Haifa

Country [34]

Israel

State/province [34]

Jerusalem

Country [35]

Israel

State/province [35]

Kfar Saba

Country [36]

Israel

State/province [36]

Petach Tikva

Country [37]

Israel

State/province [37]

Ramat-Gan

Country [38]

Italy

State/province [38]

Bologna

Country [39]

Italy

State/province [39]

Pavia

Country [40]

Korea, Republic of

State/province [40]

Incheon

Country [41]

Korea, Republic of

State/province [41]

Seoul

Country [42]

Netherlands

State/province [42]

Noord-Holland

Country [43]

Netherlands

State/province [43]

AZ Maastricht

Country [44]

Netherlands

State/province [44]

Utrecht

Country [45]

Spain

State/province [45]

Navarra

Country [46]

Spain

State/province [46]

Barcelona

Country [47]

Spain

State/province [47]

Madrid

Country [48]

Spain

State/province [48]

Majadahonda

Country [49]

Spain

State/province [49]

Salamanca

Country [50]

United Kingdom

State/province [50]

Birmingham

Country [51]

United Kingdom

State/province [51]

London

Country [52]

United Kingdom

State/province [52]

Manchester

Country [53]

United Kingdom

State/province [53]

Oxford

Funding & Sponsors

Primary sponsor type

Commercial sector/industry

Name

Millennium Pharmaceuticals, Inc.

Country

Ethics approval

Ethics application status

Summary

Brief summary

The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis.

Trial website

https://clinicaltrials.gov/study/NCT01659658

Trial related presentations / publications

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schonland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26. Erratum In: Blood. 2020 Mar 26;135(13):1071. doi: 10.1182/blood.2020005086.

Public notes

Contacts

Principal investigator

Name

Medical Director

Address

Takeda

Country

Phone

Contact person for public queries

Name

Address

Country

Phone

Contact person for scientific queries

Data sharing statement

What supporting documents are/will be available?

Type	Other Details	Attachment
Study protocol
Statistical analysis plan

Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01659658

Register a trial

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01659658